Media headlines about Nabriva Therapeutics (NASDAQ:NBRV) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nabriva Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.1761520698603 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Notable Hot Stock’s Alert: Suncor Energy Inc., (NYSE: SU), Nabriva Therapeutics plc, (NASDAQ: NBRV) – StocksNewsPro (press release) (stocksnewspro.com)
- Going Through the Figures for: Visa Inc., (NYSE: V), Nabriva Therapeutics plc, (NASDAQ: NBRV); – TNN (tradingnewsnow.com)
- Swiveling Stocks: Nabriva Therapeutics plc, (NASDAQ: NBRV), Antares Pharma, Inc., (NASDAQ: ATRS) – Global Export Lines (press release) (globalexportlines.com)
- Nabriva Therapeutics plc (NBRV) expected to achieve -1.60% earnings growth for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Nabriva Therapeutics plc (NBRV) Revamps Its Position for Performance Measures – Stock News Stop (stockmarketstop.com)
A number of equities analysts recently weighed in on NBRV shares. Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics and gave the stock a “buy” rating in a report on Friday, March 16th. Bank of America started coverage on Nabriva Therapeutics in a report on Wednesday. They issued a “buy” rating and a $10.00 price target for the company. Wedbush reaffirmed an “outperform” rating on shares of Nabriva Therapeutics in a report on Monday, March 19th. Morgan Stanley started coverage on Nabriva Therapeutics in a report on Wednesday, January 17th. They issued an “overweight” rating and a $10.00 price target for the company. Finally, Zacks Investment Research cut Nabriva Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $16.69.
WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296744/nabriva-therapeutics-nbrv-given-news-sentiment-score-of-0-18.html.
About Nabriva Therapeutics
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.